Edition:
United Kingdom

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

0.99EUR
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
€0.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
469,779
52-wk High
€5.46
52-wk Low
€0.98

Select another date:

Tue, Oct 17 2017

BRIEF-Onxeo reports commercial court of Paris decision in lawsuit against SpeBio/SpePharm​

* ‍Onxeo reports first instance decision from commercial court of Paris in lawsuit against SpeBio/SpePharm​

BRIEF-Onxeo introduces chemistry platform of decoy oligonucleotides platON

* ONXEO INTRODUCES PLATON™, A PROPRIETARY CHEMISTRY PLATFORM OF DECOY OLIGONUCLEOTIDES

BRIEF-Onxeo ‍announces preclinical data for combination of AsiDNA™ and belinostat​

* ‍ANNOUNCES COMPELLING PRECLINICAL DATA IN COMBINATION FOR ITS TWO INNOVATIVE COMPOUNDS, ASIDNA™ AND BELINOSTAT​

BRIEF-Onxeo grants exclusive worldwide license for Validive to Monopar Therapeutics

* ONXEO GRANTS EXCLUSIVE WORLDWIDE LICENSE OF VALIDIVE DEVELOPED FOR THE TREATMENT OF ORAL SEVERE MUCOSITIS TO MONOPAR THERAPEUTICS

BRIEF-Onxeo announces top-line results from ReLive Phase III study of Livatag in advanced hepatocellular carcinoma

* Onxeo announces top-line results from ReLive Phase III study of Livatag® in advanced hepatocellular carcinoma

BRIEF-Onxeo divests two non-core products to Vectans Pharma

* ONXEO DIVESTS TWO NON-CORE PRODUCTS IN ORAL PATHOLOGIES TO VECTANS PHARMA

BRIEF-Onxeo H1 net loss stable at 11.6‍​ million euros

* H1 REVENUE EUR ‍​3.4 MILLION VERSUS EUR 1.9 MILLION YEAR AGO

BRIEF-Onxeo announces positive preclinical proof of concept results for AsiDNA

* ONXEO ANNOUNCES POSITIVE PRECLINICAL PROOF OF CONCEPT RESULTS CONFIRMING ASIDNA ACTIVITY VIA SYSTEMIC ADMINISTRATION

BRIEF-Onxeo launches capital increase by means of accelerated book-build offering

* ONXEO LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOK-BUILD OFFERING

Select another date: